Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Soluble VE-cadherin and VE-cadherin Antibody in Systemic Sclerosis
NCT02212249Completed
- Sponsor
- CHU Grenoble Alpes
- Start
- May 2014
- Primary completion
- Mar 2016
- Countries
- 1
01
Overview
Open-label trial (2 arms), sponsored by CHU Grenoble Alpes. Primary endpoint: Level of soluble VE-cadherin and antibody VE-cadherin at 30 days. Started May 2014; status: completed.
Beyond the preview
Go deeper on NCT02212249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02212249.